| 000 | 01410 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250512200509.0 | ||
| 264 | 0 | _c19841227 | |
| 008 | 198412s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/s0140-6736(84)91506-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLever, A M | |
| 245 | 0 | 0 |
_aNon-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cNov 1984 |
||
| 300 |
_a1062-4 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAgammaglobulinemia _xtherapy |
| 650 | 0 | 4 |
_aAspartate Aminotransferases _xblood |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aConcanavalin A _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis C _xtransmission |
| 650 | 0 | 4 |
_aHepatitis, Viral, Human _xtransmission |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulins _xadverse effects |
| 650 | 0 | 4 | _aInjections, Intramuscular |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aT-Lymphocytes _xdrug effects |
| 700 | 1 | _aWebster, A D | |
| 700 | 1 | _aBrown, D | |
| 700 | 1 | _aThomas, H C | |
| 773 | 0 |
_tLancet (London, England) _gvol. 2 _gno. 8411 _gp. 1062-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0140-6736(84)91506-x _zAvailable from publisher's website |
| 999 |
_c6150212 _d6150212 |
||